文献速递临床免疫临床生化

临床甲状腺功能正常患者FT4和FT3可疑升高:临床发现还是分析陷阱?

Dubiously increased FT4 and FT3 levels in clinically euthyroid patients: clinical finding or analytical pitfall?
PubMed 文献 · Clin Chem Lab Med · 2022-02-25

该研究系统调查了无甲状腺疾病患者中TSH正常或亚临床升高但FT4和FT3意外升高的现象,并探索改进诊断流程和潜在病因。收集约六年内TSH在0.4-10 mU/L且FT4升高的120例样本,比较不同免疫分析法并检测总T4、总T3及异嗜性抗体阻断管效果。结果显示仅少数样本总T4升高,总T3多在参考范围内,异嗜性抗体阻断管未能减少非特异性免疫反应,建议检测总T4和总T3或使用替代设计免疫分析法以克服可疑结果。

要点

  • TSH正常或亚临床升高而FT4、FT3升高时需警惕分析干扰。
  • 建议检测总T4和总T3以验证游离甲状腺激素结果。
  • 异嗜性抗体阻断管未能有效减少非特异性免疫反应。

核心结论

  • 对于TSH、FT4和FT3可疑组合,检测总T4和总T3或使用替代设计免疫分析法有助于克服分析陷阱。

研究设计与样本

  • 收集约六年内TSH在0.4-10 mU/L且FT4升高的120例样本,比较Cobas、Liaison和Architect的FT4检测,并检测总T4、总T3及使用异嗜性抗体阻断管。

主要发现

  • Cobas检测FT4升高的120例中,Liaison也有51例升高,Architect有26例升高。
  • 总T4检测仅10/120例升高。
  • FT3升高例数在Architect、Cobas和Liaison分别为28、27和9例,总T3在70/71例中处于参考范围内。
  • 异嗜性抗体阻断管未能减少样本中的非特异性免疫反应。
  • 患者病史中未阐明明确的致病背景。

临床怎么用

  • 遇到TSH与FT4、FT3结果矛盾时,应加测总T4和总T3进行验证。
  • 可换用不同设计原理的免疫分析法复核游离甲状腺激素结果。

局限性

  • 患者病史中未能阐明明确的致病背景。
  • 异嗜性抗体阻断管在本研究样本中未能有效减少非特异性免疫反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We systematically investigated normally or subclinically increased thyroid stimulating hormone (TSH) values associated with unexpectedly increased thyroxine (FT4) and free triiodothyronine (FT3) in findings of patients without any thyroid disease. Moreover, we looked for alternatives to overcome such states with an improved diagnostic procedure and to investigate the pathogenetic background of the respective patients. METHODS: Samples with TSH concentrations within the range of 0.4-10 mU/L combined with increased concentrations of FT4 (n=120; Cobas, Roche) were collected over a period of around six years. Cobas FT4 results were compared with measurements from Liaison (DiaSorin) and Architect (Abbott) FT4 assays. For further validation all samples were measured for total thyroxine (TT4) (Cobas, Roche). Finally, FT3 and TT3 as complementary parameters were measured in samples with leftover material. To overcome potential analytical disturbances from stimulating heterophilic antibodies, we used heterophilic blocking tubes (HBTs). RESULTS: From the 120 samples with increased FT4 concentrations by Cobas, 51/120 were also increased by Liaison, and 26/120 by Architect. However, the measurement of TT4 indicated only n=10/120 increased values. The number of increased FT3 (n=71) measurements was higher in Architect>Cobas>Liaison (28>27>9). TT3 levels of 70/71 samples were within the reference interval. HBTs were inappropriate to reduce unspecific immunoreactivity in our samples. No clear pathogenetic background could be elucidated in the anamnesis of individual patients. CONCLUSIONS: To overcome dubious constellations of TSH, FT4, and FT3, it is helpful to measure TT4 and TT3 for control or to use an immunoassay with an alternative assay design for the respective parameters.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Külz M, Fellner S, Rocktäschel J, et al. Dubiously increased FT4 and FT3 levels in clinically euthyroid patients: clinical finding or analytical pitfall? Clin Chem Lab Med. 2022. PMID: 35213944. doi:10.1515/cclm-2021-1211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。